Precision imaging, utilizing molecular targeted agents, is an important tool in cancer diagnostics and guiding therapies. While there are limitations associated with single mode imaging probes, multimodal molecular imaging probes enabling target visualization through complementary imaging technologies provides an attractive alternative. However, there are several challenges associated with designing molecular probes carrying contrast agents for complementary multimodal imaging. Here, we propose a dual function antibody conjugate (DFAC) comprising an FDA approved photosensitizer Benzoporphyrin derivative (BPD) and a naphthalocyanine-based photoacoustic dye (SiNc(OH)) for multimodal infrared (IR) imaging. While fluorescence imaging, through BPD, provides sensitivity, complementing it with photoacoustic imaging, through SiNc(OH), provides a depth-resolved spatial resolution much beyond the optical diffusion limits of fluorescence measurements. Through a series of in vitro experiments, we demonstrate the development and utilization of DFACs for multimodal imaging and photodynamic treatment of squamous cell carcinoma (A431) cell line. The proposed DFACs have potential use in precision imaging applications such as guiding tumor resection surgeries and photodynamic treatment of residual microscopic disease thereby minimizing local recurrence. The data demonstrated in this study merits further investigation for its preclinical and clinical translation.

中文翻译：

---

用于癌细胞多模式成像和光免疫治疗的双功能抗体偶联物

利用分子靶向药物的精确成像是癌症诊断和指导治疗的重要工具。虽然单模成像探针存在局限性，但通过互补成像技术实现目标可视化的多模态分子成像探针提供了一种有吸引力的替代方案。然而，在设计携带用于互补多模态成像的造影剂的分子探针方面存在一些挑战。在这里，我们提出了一种双功能抗体偶联物 (DFAC)，包含 FDA 批准的光敏剂苯并卟啉衍生物 (BPD) 和基于萘酞菁的光声染料 (SiNc(OH))，用于多峰红外 (IR) 成像。虽然荧光成像通过 BPD 提供灵敏度，但通过 SiNc(OH) 与光声成像相辅相成，提供远远超出荧光测量的光扩散极限的深度分辨空间分辨率。通过一系列在体外实验中，我们展示了 DFAC 在鳞状细胞癌 (A431) 细胞系的多模式成像和光动力治疗中的开发和利用。拟议的 DFAC 在精确成像应用中具有潜在用途，例如指导肿瘤切除手术和残余微观疾病的光动力治疗，从而最大限度地减少局部复发。本研究中展示的数据值得进一步研究其临床前和临床转化。